Clampdown on Drug TV Ads

The White House ordered FDA and HHS to toughen enforcement of direct‑to‑consumer prescription drug advertising by requiring clearer risk disclosures and preventing overstated benefits or steering patients toward brands over generics. If carried out, this would curb misleading pharma marketing and could reduce the influence of ad dollars on how the public learns about medicines. — This move links public health and media economics, potentially reshaping drug pricing pressures and the balance between commercial speech and patient protection.